



GKB Ophthalmics Ltd.

16-A, Tivim Industrial Estate, Mapusa, Goa 403 526 (INDIA)
CIN.: L26109GA1981PLC000469

Tel. : (91 832) 2257253 / 6714444

Fax : (91 832) 2257044

E-mail : gkbophthalmics@gkb.net

Website : www.gkb.net

GKB/ STK- EXCH
August 11, 2023

To,
The Listing Department
BSE Limited
Phiroze Jeejubhoy Towers, Dalal Street
Mumbai - 400 001

Dear Sir,

Ref : Scrip Code No. : 533212

Sub : Statement of deviation(s) or variation(s) under Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations , 2015

Pursuant to Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD1/162/2019, dated December 24, 2019, we would like to inform you that the Audit Committee in their meeting held on August 11, 2023, has reviewed the utilisation of funds which were raised by means of preferential allotment and noted that there was no utilization of funds, during the quarter ended June 30, 2023.

Enclosed please find the Statement as per the format, giving details of the same.

Kindly take the information on records.

Thanking you

Yours faithfully,
For GKB Ophthalmics Limited

Gurudas Sawant
Chief Financial Officer



Statement of Deviation / Variation in utilisation of funds raised	
Name of listed entity	GKB Ophthalmics Limited
Mode of Fund Raising	Public Issues / Rights Issues / Preferential Issues / QIP / Others
Date of Raising Funds	July 27, 2018 and January 22, 2020
Amount Raised	Equity Shares - Rs. 7,54,85,000 Warrants - Rs. 2,90,62,500 Warrants - Rs. 4,65,00,000 (75% of balance warrant money received on or before January 21, 2020 , with respect to 4,00,000 warrants)
Report filed for Quarter ended	June 30, 2023
Monitoring Agency	applicable / not applicable
Monitoring Agency Name, if applicable	Yes / No
Is there a Deviation / Variation in use of funds raised	There was no utilization of funds for the quarter ended June 30, 2023.
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	--
If Yes, Date of shareholder Approval	--
Explanation for the Deviation / Variation	--
Comments of the Audit Committee after review	The Audit Committee noted that there was no utilization of funds for the quarter ended June 30, 2023.
Comments of the auditors, if any	--

